Spero Therapeutics (NASDAQ: SPRO) reported Q4 EPS of $0.53, $0.73 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $41.3 million versus the consensus estimate of $26 million.

For earnings history and earnings-related data on SmartPros Ltd. (SPRO) click here.